Drug and Poison Information Center, Faculty of pharmacy, Tanta University, Tanta, Egypt
Research Article
The effect of atherothrombotic markers in newly diagnosed patients with type 2 diabetes mellitus
Author(s): Bassant M Mahboub*, Sahar M El-Haggar, Yasser M Abdelraouf and Gamal A Elazab
Objective: This study aimed to evaluate the effect of adding vildagliptin to metformin therapy on major CV risk parameters in newly diagnosed patients with type 2 diabetes mellitus (T2DM).
Methods: Forty three eligible patients were prospectively randomized to receive combined vildagliptin/metformin therapy or metformin alone. Anthropometric measurements, blood pressure (BP), glycated hemoglobin (HbA1c), lipid profile, plasminogen activator inhibitor-1 (PAI-1), high sensitivity C-reactive protein (hs-CRP), and total antioxidant capacity (TAC) were assessed at baseline and after 12 weeks.
Results: Forty patients completed the study (20 in each group). At baseline, no significant differences were observed between groups in all studied parameters. After 12 weeks, combined vildagliptin/metformin showed significant reductio.. View More»
